These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

455 related items for PubMed ID: 26635456

  • 1. Effects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related Macular Degeneration.
    Lee KH, Chin HS, Kim NR, Moon YS.
    Korean J Ophthalmol; 2015 Dec; 29(6):396-403. PubMed ID: 26635456
    [Abstract] [Full Text] [Related]

  • 2. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Krishnan R, Arora R, De Salvo G, Stinghe A, Severn PS, Pal B, Goverdhan S.
    Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
    [Abstract] [Full Text] [Related]

  • 3. Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Ciulla TA, Ying GS, Maguire MG, Martin DF, Jaffe GJ, Grunwald JE, Daniel E, Toth CA, Comparison of Age-Related Macular Degeneration Treatments Trials Research Group.
    Ophthalmology; 2015 Jun; 122(6):1203-11. PubMed ID: 25824327
    [Abstract] [Full Text] [Related]

  • 4. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE, Kanadani TM, Pereira FB, Nehemy MB.
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [Abstract] [Full Text] [Related]

  • 5. INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX).
    Houston SK, Rayess N, Cohen MN, Ho AC, Regillo CD.
    Retina; 2015 Sep; 35(9):1757-64. PubMed ID: 26110596
    [Abstract] [Full Text] [Related]

  • 6. Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration.
    Kanadani TCM, Dos Reis Veloso CE, Dorairaj S, Nehemy MB.
    Ophthalmic Res; 2017 Sep; 58(1):18-26. PubMed ID: 28301850
    [Abstract] [Full Text] [Related]

  • 7. Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration.
    Mayr-Sponer U, Waldstein SM, Kundi M, Ritter M, Golbaz I, Heiling U, Papp A, Simader C, Schmidt-Erfurth U.
    Ophthalmology; 2013 Dec; 120(12):2620-2629. PubMed ID: 23870300
    [Abstract] [Full Text] [Related]

  • 8. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice.
    Pinheiro-Costa J, Costa JM, Beato JN, Freitas-da-Costa P, Brandão E, Falcão MS, Falcão-Reis F, Carneiro ÂM.
    Ophthalmologica; 2015 Dec; 233(3-4):155-61. PubMed ID: 25896317
    [Abstract] [Full Text] [Related]

  • 9. THE INFLUENCE OF VITREOMACULAR ADHESION ON OUTCOMES AFTER AFLIBERCEPT THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    McKibbin MA, Suter CA, Willis TA.
    Retina; 2015 Oct; 35(10):1951-6. PubMed ID: 25932561
    [Abstract] [Full Text] [Related]

  • 10. Retinal and choroidal thickness changes after single anti-VEGF injection in neovascular age-related macular degeneration: ranibizumab vs bevacizumab.
    Sizmaz S, Kucukerdonmez C, Kal A, Pinarci EY, Canan H, Yilmaz G.
    Eur J Ophthalmol; 2014 Oct; 24(6):904-10. PubMed ID: 24803153
    [Abstract] [Full Text] [Related]

  • 11. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases.
    Ou WC, Brown DM, Payne JF, Wykoff CC.
    Am J Ophthalmol; 2017 Aug; 180():8-17. PubMed ID: 28549848
    [Abstract] [Full Text] [Related]

  • 12. [Responses to ranibizumab in wet age-related macular degeneration patients with vitreomacular traction].
    Filloy A, Arias L.
    Arch Soc Esp Oftalmol; 2013 Oct; 88(10):380-6. PubMed ID: 24060301
    [Abstract] [Full Text] [Related]

  • 13. Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study.
    Hatz K, Prünte C.
    Acta Ophthalmol; 2017 Feb; 95(1):e67-e72. PubMed ID: 27009503
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
    Shin JY, Kwon KY, Byeon SH.
    Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
    [Abstract] [Full Text] [Related]

  • 18. Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up.
    Inan S, Baysal Z, Inan UU.
    Curr Eye Res; 2019 Aug; 44(8):908-915. PubMed ID: 30909756
    [Abstract] [Full Text] [Related]

  • 19. Effects of vitreomacular adhesion on ranibizumab treatment in Japanese patients with age-related macular degeneration.
    Nomura Y, Takahashi H, Tan X, Fujimura S, Obata R, Yanagi Y.
    Jpn J Ophthalmol; 2014 Sep; 58(5):443-7. PubMed ID: 25096269
    [Abstract] [Full Text] [Related]

  • 20. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
    Baek JS, Cho HJ, Cho SW, Kim CG, Kim JW.
    Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.